
Sign up to save your podcasts
Or


touchFOCUS for touchONCOLOGY
In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.
The expert:
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc.
By touchpodcasttouchFOCUS for touchONCOLOGY
In this concise interview, Dr Christine Bestvina discusses the key clinical questions surrounding currently approved RET inhibitors in NSCLC.
The expert:
This touchPODCAST is for HCPs outside the UK.
This activity is funded by an independent medical education grant from Rigel Pharmaceuticals Inc.